T. Rowe Price Associates’s Alpine Immune Sciences, Inc. Common Stock ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,080,220
| Closed | -$122M | – | 3072 |
|
|
2024
Q1 | $122M | Buy |
3,080,220
+1,392,942
| +83% | +$55.2M | 0.02% | 506 |
|
|
2023
Q4 | $32.2M | Buy |
1,687,278
+290,834
| +21% | +$5.54M | ﹤0.01% | 828 |
|
|
2023
Q3 | $16M | Buy |
1,396,444
+1,374,704
| +6,323% | +$15.7M | ﹤0.01% | 971 |
|
|
2023
Q2 | $224K | Buy |
21,740
+2,115
| +11% | +$21.8K | ﹤0.01% | 2478 |
|
|
2023
Q1 | $152K | Buy |
19,625
+224
| +1% | +$1.74K | ﹤0.01% | 2591 |
|
|
2022
Q4 | $143K | Buy |
19,401
+6,786
| +54% | +$50K | ﹤0.01% | 2632 |
|
|
2022
Q3 | $91K | Buy |
+12,615
| New | +$91K | ﹤0.01% | 2744 |
|